147 related articles for article (PubMed ID: 15005736)
21. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
23. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
24. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
25. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.
Klunker S; Saggar LR; Seyfert-Margolis V; Asare AL; Casale TB; Durham SR; Francis JN;
J Allergy Clin Immunol; 2007 Sep; 120(3):688-95. PubMed ID: 17631952
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
[TBL] [Abstract][Full Text] [Related]
27. An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.
Selb R; Eckl-Dorna J; Vrtala S; Valenta R; Niederberger V
Allergy; 2013 Sep; 68(9):1199-202. PubMed ID: 23998344
[TBL] [Abstract][Full Text] [Related]
28. Soybean allergy in patients allergic to birch pollen: clinical investigation and molecular characterization of allergens.
Mittag D; Vieths S; Vogel L; Becker WM; Rihs HP; Helbling A; Wüthrich B; Ballmer-Weber BK
J Allergy Clin Immunol; 2004 Jan; 113(1):148-54. PubMed ID: 14713921
[TBL] [Abstract][Full Text] [Related]
29. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
Winther L; Malling HJ; Mosbech H
Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
[TBL] [Abstract][Full Text] [Related]
30. Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
Kopac P; Rudin M; Gentinetta T; Gerber R; Pichler Ch; Hausmann O; Schnyder B; Pichler WJ
Allergy; 2012 Feb; 67(2):280-5. PubMed ID: 22070352
[TBL] [Abstract][Full Text] [Related]
31. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy.
Mittag D; Akkerdaas J; Ballmer-Weber BK; Vogel L; Wensing M; Becker WM; Koppelman SJ; Knulst AC; Helbling A; Hefle SL; Van Ree R; Vieths S
J Allergy Clin Immunol; 2004 Dec; 114(6):1410-7. PubMed ID: 15577846
[TBL] [Abstract][Full Text] [Related]
32. Can serum white birch (Betula verrucosa) pollen antigen (Bet v 1) immunoglobulin E measurement distinguish between sensitization and allergy?
Ciprandi G; Comite P; Ferrero F; Minale P; Voltolini S; Bignardi D; Fontana V; Bruzzone M; Troise C; Mussap M
Int Forum Allergy Rhinol; 2015 Dec; 5(12):1151-5. PubMed ID: 26250401
[TBL] [Abstract][Full Text] [Related]
33. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.
Wachholz PA; Soni NK; Till SJ; Durham SR
J Allergy Clin Immunol; 2003 Nov; 112(5):915-22. PubMed ID: 14610480
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
37. Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study.
Eckl-Dorna J; Fröschl R; Lupinek C; Kiss R; Gattinger P; Marth K; Campana R; Mittermann I; Blatt K; Valent P; Selb R; Mayer A; Gangl K; Steiner I; Gamper J; Perkmann T; Zieglmayer P; Gevaert P; Valenta R; Niederberger V
Allergy; 2018 May; 73(5):1003-1012. PubMed ID: 29083477
[TBL] [Abstract][Full Text] [Related]
38. The Clinical Impact of Bet v 6 in Birch Pollen-Sensitized Patients.
Gellrich D; Eder K; San Nicoló M; Berghaus A; Gröger M
Int Arch Allergy Immunol; 2017; 173(1):34-43. PubMed ID: 28494455
[TBL] [Abstract][Full Text] [Related]
39. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
40. Immunoglobulin G4-antibodies to rBet v 1 and risk of sensitization and atopic disease in the child.
Kihlström A; Hedlin G; Pershagen G; Troye-Blomberg M; Härfast B; Lilja G
Clin Exp Allergy; 2005 Dec; 35(12):1542-9. PubMed ID: 16393319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
